Literature DB >> 27936348

Current prospects and future challenges for nasal vaccine delivery.

Helmy Yusuf1, Vicky Kett2.   

Abstract

Nasal delivery offers many benefits over traditional approaches to vaccine administration. These include ease of administration without needles that reduces issues associated with needlestick injuries and disposal. Additionally, this route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body. Increased acceptance of nasal vaccine products in both adults and children has led to a burgeoning pipeline of nasal delivery technology. Key challenges and opportunities for the future will include translating in vivo data to clinical outcomes. Particular focus should be brought to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that stand to benefit from this unique mucosal route.

Entities:  

Keywords:  influenza; mucosal; nasal; needle-free; vaccine

Mesh:

Substances:

Year:  2016        PMID: 27936348      PMCID: PMC5287317          DOI: 10.1080/21645515.2016.1239668

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  139 in total

1.  Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

Authors:  P Durrer; U Glück; C Spyr; A B Lang; R Zurbriggen; C Herzog; R Glück
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

Review 2.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 3.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

4.  Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.

Authors:  M Jaber Hossain; Melissa Bourgeois; Fu-Shi Quan; Aleksandr S Lipatov; Jae-Min Song; Li-Mei Chen; Richard W Compans; Ian York; Sang-Moo Kang; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2011-10-26

Review 5.  Protective role of Th17 cells in pulmonary infection.

Authors:  Jitendra Singh Rathore; Yan Wang
Journal:  Vaccine       Date:  2016-02-13       Impact factor: 3.641

6.  An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

Authors:  Lissette S Velasquez; Brooke E Hjelm; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Clin Vaccine Immunol       Date:  2010-10-20

7.  Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity.

Authors:  M G Cusi; R Zurbriggen; M Valassina; S Bianchi; P Durrer; P E Valensin; M Donati; R Glück
Journal:  Virology       Date:  2000-11-10       Impact factor: 3.616

8.  Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

Authors:  Daqing Wang; Mary E Christopher; Les P Nagata; Monika A Zabielski; Hongduo Li; Jonathan P Wong; John Samuel
Journal:  J Clin Virol       Date:  2004-12       Impact factor: 3.168

9.  Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.

Authors:  Marien I de Jonge; Hendrik Jan Hamstra; Wim Jiskoot; Paul Roholl; Neil A Williams; Jacob Dankert; Loek van Alphen; Peter van der Ley
Journal:  Vaccine       Date:  2004-09-28       Impact factor: 3.641

10.  NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine.

Authors:  Carmelo Luci; Selma Bekri; Franck Bihl; Jonathan Pini; Pierre Bourdely; Kelly Nouhen; Angélique Malgogne; Thierry Walzer; Véronique M Braud; Fabienne Anjuère
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more
  32 in total

1.  The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.

Authors:  Atsushi Kawai; Yasuyuki Yamamoto; Takuto Nogimori; Kohei Takeshita; Takuya Yamamoto; Yasuo Yoshioka
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

Review 2.  Nasal vaccine as a booster shot: a viable solution to restrict pandemic?

Authors:  Sarasa Meenakshi; V Udaya Kumar; Sameer Dhingra; Krishna Murti
Journal:  Clin Exp Vaccine Res       Date:  2022-05-31

Review 3.  Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.

Authors:  William Walkowski; Justin Bassett; Manmeet Bhalla; Blaine A Pfeifer; Elsa N Bou Ghanem
Journal:  Vaccines (Basel)       Date:  2021-06-02

4.  Intranasal Vaccination Strategy to Control the COVID-19 Pandemic from a Veterinary Medicine Perspective.

Authors:  Salleh Annas; Mohd Zamri-Saad
Journal:  Animals (Basel)       Date:  2021-06-24       Impact factor: 2.752

Review 5.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

Review 6.  Mucosal immunoglobulins of teleost fish: A decade of advances.

Authors:  Irene Salinas; Álvaro Fernández-Montero; Yang Ding; J Oriol Sunyer
Journal:  Dev Comp Immunol       Date:  2021-03-27       Impact factor: 3.605

7.  A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.

Authors:  Traci L Bricker; Tamarand L Darling; Ahmed O Hassan; Houda H Harastani; Allison Soung; Xiaoping Jiang; Ya-Nan Dai; Haiyan Zhao; Lucas J Adams; Michael J Holtzman; Adam L Bailey; James Brett Case; Daved H Fremont; Robyn Klein; Michael S Diamond; Adrianus C M Boon
Journal:  Cell Rep       Date:  2021-06-29       Impact factor: 9.995

Review 8.  Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.

Authors:  Lantian Lu; Viet Tram Duong; Ahmed O Shalash; Mariusz Skwarczynski; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2021-05-28

9.  Curdlan sulfate-O-linked quaternized chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination.

Authors:  Shu Zhang; Shengshi Huang; Lu Lu; Xinlei Song; Pingli Li; Fengshan Wang
Journal:  Int J Nanomedicine       Date:  2018-04-18

Review 10.  Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.

Authors:  Vivek P Chavda; Lalitkumar K Vora; Anjali K Pandya; Vandana B Patravale
Journal:  Drug Discov Today       Date:  2021-07-29       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.